Relapsed or Refractory Follicular and Mantle Cell Lymphomas: Pharmacist-Driven Strategies to Optimize Patient Management

Publication
Article
Specialty Pharmacy TimesJune 2020
Volume 3
Issue 2

At the completion of this activity, the participant will be able to determine appropriate treatment options for a patient with relapsed or refractory FL or MCL.

THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM PHARMACYCLICS LLC, AN ABBVIE COMPANY AND JANSSEN BIOTECH, INC., AND CELGENE CORPORATION.

FACULTY

Deborah A. Hass, PharmD, BCOP, BCPS

Associate Professor of Pharmacy Practice

West Coast University School of Pharmacy

Los Angeles, California

At the completion of this activity, the participant will be able to:

  • Explain the role of prognostic indexes in treatment selection for patients with relapsed or refractory follicular lymphoma (FL) and mantle cell lymphoma (MCL)
  • Determine appropriate treatment options for a patient with relapsed or refractory FL or MCL based on disease- and patient-specific characteristics
  • Identify supportive care needs and medication adherence strategies for a patient with relapsed or refractory FL or MCL

TARGET AUDIENCE: Clinical pharmacists, specialty pharmacists, and oncology pharmacists

ACTIVITY TYPE:Application

RELEASE DATE: June 15, 2020EXPIRATION DATE: January 15, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.

Related Videos
Team of care workers with women at the center -- Image credit: Delmaine Donson/peopleimages.com | stock.adobe.com
Image Credit: SciePro - stock.adobe.com
Pharmacist preparing high-risk chemotherapy
Image Credit: © jarun011 - stock.adobe.com
MP Studio - stock.adobe.com
Image credit: David A Litman | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.